EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Randomized Phase 2 Trial of Freeze-dried Platelets for Bleeding in Thrombocytopenic Patients Hematologic Malignancies

Maro Ohanian, Keith A. Moskowitz, Jeremy G. Perkins, Betty Y. S. Kim, Noah Nathan Chasen, Cristhiam Rojas-Hernandez, Maria Abreu-Blanco, Lisa Booth, Terry Gernsheimer, G. Michael Fitzpatrick, Fleur Aung, Jose A. Cancelas

Blood Vessels, Thrombosis & Hemostasis · 2026-09 · 100227

DOI: 10.1016/j.bvth.2026.100227 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Blood Vessels, Thrombosis & Hemostasis, 2026-09. Verfasst von Maro Ohanian und 11 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Treatment of bleeding patients with hematologic malignancies is hampered by the limited hemostatic efficacy of conventional platelet products and frequent inventory platelet shortages. Alternative, off-the-shelf, potent hemostatic options are needed. A prospective, randomized, open-label, Phase 2, dose-ranging trial tested the safety and efficacy of a freeze-dried platelet-derived hemostatic (FPH) product in bleeding thrombocytopenic patients with hematologic malignancies ( https://clinicaltrials.gov/study/NCT04631211 ). Nineteen patients with hematologic malignancies were randomized and received one of three dose levels of FPH (low-dose [n = 4], medium-dose [n = 5], high-dose [n = 7]), or room temperature platelets (control, n = 3). The primary efficacy endpoint—cessation or decreased bleeding at the primary bleeding site within 24 hours— was achieved in most patients receiving FPH: low-dose (75%), medium-dose (60%), and high-dose (57%), compared with 33% (1 of 3) in the control group. Importantly, ex-vivo analysis of blood samples demonstrated FPH retained hemostatic activity independent of patient’s anti-HLA or anti-platelet antibody status. Two additional acute myeloid leukemia patients with refractory Grade IV intracranial bleeds received compassionate-use FPH and achieved resolution of the intracranial bleed. Thus, FPH may represent a potent, safe alternative to treat bleeding patients with hematological malignancies.

Zitieren

APA

Ohanian, M., Moskowitz, K. A., Perkins, J. G., Kim, B. Y. S., Chasen, N. N., Rojas-Hernandez, C., Abreu-Blanco, M., Booth, L., Gernsheimer, T., Fitzpatrick, G. M., Aung, F., & Cancelas, J. A. (2026). Randomized Phase 2 Trial of Freeze-dried Platelets for Bleeding in Thrombocytopenic Patients Hematologic Malignancies. Blood Vessels, Thrombosis & Hemostasis, 100227. https://doi.org/10.1016/j.bvth.2026.100227

Vancouver

Ohanian M, Moskowitz KA, Perkins JG, Kim BYS, Chasen NN, Rojas-Hernandez C, et al. Randomized Phase 2 Trial of Freeze-dried Platelets for Bleeding in Thrombocytopenic Patients Hematologic Malignancies. Blood Vessels, Thrombosis & Hemostasis. 2026:100227. doi:10.1016/j.bvth.2026.100227

BibTeX
@article{Ohanian2026,
  author = {Ohanian, Maro and Moskowitz, Keith A. and Perkins, Jeremy G. and Kim, Betty Y. S. and Chasen, Noah Nathan and Rojas-Hernandez, Cristhiam and Abreu-Blanco, Maria and Booth, Lisa and Gernsheimer, Terry and Fitzpatrick, G. Michael and Aung, Fleur and Cancelas, Jose A.},
  title = {Randomized Phase 2 Trial of Freeze-dried Platelets for Bleeding in Thrombocytopenic Patients Hematologic Malignancies},
  journal = {Blood Vessels, Thrombosis & Hemostasis},
  year = {2026},
  pages = {100227},
  doi = {10.1016/j.bvth.2026.100227}
}
Kostenlos starten →